The Neurostimulation Devices Market (2nd Edition), 2018-2030' report features an extensive study of the current landscape and future outlook of the growing market for neurostimulation devices. The focus of this study is on invasive neurostimulation devices, such as devices for spinal cord stimulation (SCS), deep brain stimulation (DBS), spinal nerve stimulation (SNS), vagus nerve stimulation (VNS), other cranial nerve stimulation (Other CNS) and other variants of neurostimulation devices.
The National Academy of Medicine indicates that as many as 100 million people in the US suffer from some form of pain, which has been shown to be associated with a socioeconomic burden of around USD 600 billion per year, in treatment costs and lost productivity. Further, it has been estimated that nearly 1 million people in America suffer from Parkinson's disease, with approximately 60,000 new patients being diagnosed every year.
Over the past few decades, the prevalence of such chronic disorders has grown at an alarming rate. In fact, a recent World Health Organization's Global Burden of Disease study recognized these chronic conditions as one of the leading causes of deteriorating public health in the world. Such clinical conditions have often been shown to result in serious physical, cognitive and psychosocial consequences in patients. This indicates an urgent need for novel and effective treatment methods as the drawbacks of existing treatment options (such as high risk of addiction/abuse associated with long-term use of oral opioids, and complications due to complex surgical procedures) are substantial.
Amongst other elements, the report features:
A detailed assessment of the overall landscape of neurostimulation devices market, featuring the contributions of various companies engaged in this domain and highlighting key device specifications (size, weight, battery type, battery life, number of electrodes, type of programming, and MRI compatibility), along with information on different types of neurostimulation devices, target therapeutic areas, and regulatory approvals received across various geographies.
A comprehensive product competitiveness analysis, taking into consideration the supplier power and specific device-related parameters, such as the number of target indications, target nerves, regulatory approvals, and key device specifications.
Comprehensive profiles of developers of leading neurostimulation devices (shortlisted on the basis of the product competitiveness analysis), featuring an overview of the company, its financial information (if available), and a detailed description of the device(s). Each profile also includes a list of recent developments, highlighting the achievements, partnership activity, and the likely strategies that may be adopted by these players to fuel growth in the foreseen future.
An elaborate discussion on the regulatory landscape related to medical devices across various geographies, namely North America (the US and Canada), Europe (the UK, Germany, France, Spain and Italy), and Asia-Pacific (Australia, China and Japan). The information covers details on the payer mix and the reimbursement processes of various public/private organizations across these geographies.
A detailed brand positioning analysis of leading industry players (shortlisted on the basis of strength of product portfolio), highlighting the current perceptions regarding their proprietary brands across different device types, taking into consideration several aspects, such as strength / diversity of product portfolio, extent of patent portfolio, recent collaborations, number of target indications and regulatory approvals, and the overall market positioning of the players.
An in-depth analysis of the patents that have been published since 2013. The analysis also highlights the key trends associated with these patents, including patent type, regional applicability, CPC classification, IP litigations, emerging areas, leading industry players (in terms of the number of patents filed/granted), and patent benchmarking and valuation.
A comprehensive clinical trial analysis of completed, ongoing and planned studies of various neurostimulation devices. For the purpose of this analysis, we looked at the clinical studies that have been last updated in 2013, and analyzed them on the basis of various parameters, such as current trial status, regional distribution, leading industry and non-industry players, key indications, and enrolled patient population across different geographies.
An analysis of the partnerships that have been established in the recent past, covering product development/commercialization agreements, R&D collaborations, technology licensing deals, distribution agreements, mergers/acquisitions, and others.
An analysis of investments made at various stages of product development/commercialization; these include seed financing, venture capital financing, debt financing and grants/awards received by the companies that are operating in this domain.
A comprehensive list of non-invasive neurostimulation devices, along with information on their developers, various types of non-invasive technologies used, target therapeutic areas, and development/approval status of the devices.
An elaborate discussion on the upcoming opportunities/trends in the field of neurostimulation devices that are likely to impact the evolution of this market over the coming years.
One of the key objectives of the report was to estimate the existing market size and potential growth opportunities for neurostimulation devices. Based on multiple parameters, such as target patient population, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market over the period 2018-2030.
The report provides sales forecasts for the overall neurostimulation devices market with detailed market segmentation on the basis of type neurostimulation devices (SCS, DBS, VNS, and other types), indication (chronic pain, dystonia, epilepsy, essential tremor, heart failure, major depressive disorder, Parkinson's disease, obsessive-compulsive disorder, overactive bladder, sleep apnea), MRI compatibility (MRI compatible and MRI non-compatible), and the geographical distribution of the market (US, Canada, UK, Germany, France, Spain, Italy, Australia, China, and Japan).
In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios portraying the conservative, base and optimistic tracks of the industry's evolution.
Key Topics Covered:
1. Preface
2. Executive Summary
3. Introduction
4. Regulatory And Reimbursement Landscape For Medical Devices
5. Current Market Landscape
6. Spinal Cord Stimulation
7. Deep Brain Stimulation
8. Peripheral Nerve Stimulation
9. Brand Positioning Analysis
10. Patent Analysis
11. Clinical Trial Analysis
12. Collaborations And Partnerships
13. Funding And Investment Analysis
14. Market Forecast
15. Future Growth Opportunities
16. Executive Insights
17. Appendix 1: List Of Non-Invasive Neurostimulation Devices
18. Appendix 2: Tabulated Data
19. Appendix 3: List Of Companies And Organizations
Abbott
Aberdare Ventures
Academy Medical Center
Accelmed Growth Partners
Action Potential Venture Capital
AcuKnee
AdvaStim
Advent Life Sciences
Aetion
Aetna
AG2R La Mondiale
Alan Neuromedical Technologies
ALC Healthcare
Alere
Aleva Neurotherapeutics
Alfred Mann Foundation
Allergan
Allianz
American Academy of Neurology
American Academy of Pain Medicine
American Medical Association
Amzak Health
Andera Partners
Anomali
Antares Capital
Anthem
Aperture Venture Partners
ARAG Group
Atlante Ventures
Atrotech
Attivo Networks
Aucta Technologies
Autonomic Technologies
Autonomix Medical
Avery Biomedical Devices
Aviva
AXA PPP Healthcare
Axilum Robotics
Axiobionics
Axonic Capital
Axonics Modulation Technologies
b-to-v Partners
Banexi Ventures
Barclays
Bayer
BB Biotech Ventures
BC Platforms
Becton Dickinson
Beijing PINS Medical
Beijing Tiantan Hospital
Biegler
BioControl Medical
BioElectronics
Bioinduction
BioMedical Life Systems
BioMedPartners
Bioness
BioScience Managers
BioWave
BioWin
BlueWind Medical
Boston Scientific
Brain State Technologies
Brainlab
BrainsGate
BrainsWay
Bupa
Cala Health
Calmare Therapeutics
Canadian Agency for Drugs and Technologies in Health
Cancer Prevention and Research Institute of Texas
Capricorn Venture Partners
Carbon Black
Cardionomic
Carlos III Health Institute
Case Western Reserve University
Caser Seguros
Catholic University of Leuven
CBC Banque & Assurance
CEFALY Technology
Celgene
CensorNet
Center for Sensorimotor Neural Engineering
Centers for Medicare & Medicaid Services
Centripetal Networks
Centro of Construction of Cardiac Stimulators of Uruguay
Cerbomed
Cerevast Medical
Certara
Cervel Neurotech
Chattem
Cibiem
CICA
Cigna
Clearly Present Foundation
Cleveland Clinic
Clinakos
Clinigen Group
Cogentix Medical
Coridea
Cormorant Asset Management
Cosman Medical
Covidien
CrowdStrike
Crdit Mutuel Group
CVRx
Cylance
Darktrace
Deep Brain Innovations
Defense Advanced Research Projects Agency
Deutsche Krankenversicherung
DEYMED Diagnostic
Dolphin Neurostim
Dr. Langer Medical
DyAnsys
EaglePicher Medical Power
EBS Technologies
electroCore
ElectroMedical Technologies
Electronic Waveform Lab
Elron Electronic Industries
ELvation
Endeavour Vision
Endonovo Therapeutics
EndoStim
eNeura
Enopace Biomedical
Enspire DBS Therapy
Epimed International
ERGO Group
Evergreen Medical Technologies
Evidera
Exabeam
Expatriate Healthcare
F3F
Federal Holding and Investment Company
Finetech Medical
FireEye
Firstkind
Fisher Wallace Laboratories
Flashpoint
Flatiron Health
Flow Neuroscience
Fogarty Institute for Innovation
Forbion Capital Partners
Forrestal Capital
Fortinet
Fountain Healthcare Partners
Freedom Health
French National Authority for Health
Frontcourt Ventures
Functional Neuromodulation
FundRx
Gala Therapeutics
Galvani Bioelectronics
Generali Deutschland
German Institute of Medical Documentation and Information
Gigamon
Gilde Healthcare Partners
GiMer Medical
Gimv
GlaxoSmithKline
Gradient Medical
Greatbatch
Green Park & Golf Ventures
GTX Medical
Hannover Re
HBM Healthcare Investments
HealthCore
Helius Medical Technologies
Helpucover
HiDow
High-Tech Grnderfonds
Hollywog
Horowitz Group
Humana
Humanitas Clinical Institute
ICON
INC Research
InCube Labs
Indegene
IndependiCare
Ingress Health
Initiative Capital Romandie
INKEF Capital
Innogest Capital
Innovative Health Solutions
Inspire Medical Systems
Institute for Hospital Remuneration System
Institute for Industrial Science
Institute for Quality and Efficiency in Health Care
Institute of Hospitalization and Care of Scientific Character
Institute of Medical Arts
InterWest Partners
InterX Technologies
IntraPace
IPF Partners
IQVIA
iTENS
Johari Digital Healthcare
Johnson & Johnson
JumpStart
Kairuku
Kaiser Permanente
KCK Group
Kinled Holding
Kleiner Perkins
La Luxembourgeoise
LABORIE Medical Technologies
Legend Capital Management
Leonite Capital
Lightstone Ventures
Linguamatics
LivaNova
LogRhythm
Lone Star Neuromodulation
Longitude Capital
LSP
Lungpacer Medical
MAAF Assurances
MAG & More
Magstim
MagVenture
Mainstay Medical
Massachusetts Life Science Center
Mayo Clinic
Mayo Foundation for Medical Education and Research
McAfee
McKesson
MDC Partners
Meagan Medical
Med-Ally
Medaffcon
Medi-Line
Medical University of South Carolina
Medicines and Healthcare products Regulatory Agency
Medisana
MedSec
Medtronic
MEMStim
Mercy
Metavention
Micro-Leads
MicroTransponder
Minnetronix
Morgenthaler
Munich Re
MyndTec
National Agency for Medicines and Health Products Safety
National Engineering Laboratory for Neuromodulation
National Institute of Excellence in Health and Social Services
National Institute of Health and Clinical Excellence
National Institute of Medical Sciences and Nutrition Salvador Zubiran
Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Neurology Devices
Povezani linkovi:
Autor: Copyright GlobeNewswire, Inc. 2016. All rights reserved. You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.
Realno vreme